Results 311 to 320 of about 769,731 (345)
Some of the next articles are maybe not open access.
Critical Reviews in Oncology/Hematology, 2006
Ovarian cancer accounts for 4% of all cancers in women and is the leading cause of death from gynaecologic malignancies. Because early-stage ovarian cancer is generally asymptomatic, approximately 75% of women present with advanced disease at diagnosis. Survival is highly dependent on stage of disease: 5-year survival in patients with early-stage is 80-
COLOMBO, NICOLETTA +6 more
openaire +2 more sources
Ovarian cancer accounts for 4% of all cancers in women and is the leading cause of death from gynaecologic malignancies. Because early-stage ovarian cancer is generally asymptomatic, approximately 75% of women present with advanced disease at diagnosis. Survival is highly dependent on stage of disease: 5-year survival in patients with early-stage is 80-
COLOMBO, NICOLETTA +6 more
openaire +2 more sources
International Journal of Gynecological Cancer, 2008
Mucinous epithelial ovarian cancer (mEOC) accounts for approximately 10% of EOCs. Patients presenting with early-stage disease have an excellent prognosis, however, those with advanced disease have a poor outcome with relative resistance to standard ovarian cancer chemotherapy.
M L, Harrison, C, Jameson, M E, Gore
openaire +2 more sources
Mucinous epithelial ovarian cancer (mEOC) accounts for approximately 10% of EOCs. Patients presenting with early-stage disease have an excellent prognosis, however, those with advanced disease have a poor outcome with relative resistance to standard ovarian cancer chemotherapy.
M L, Harrison, C, Jameson, M E, Gore
openaire +2 more sources
Seminars in Oncology Nursing, 2002
To review the progress in the management of ovarian cancer in the last decade and future directions.Research studies, review articles, and abstracts.There is an increased understanding of ovarian cancer biology, the genetic basis for hereditary ovarian cancer, staging and the role of cytoreductive surgery, and more effective chemotherapy, resulting in ...
openaire +2 more sources
To review the progress in the management of ovarian cancer in the last decade and future directions.Research studies, review articles, and abstracts.There is an increased understanding of ovarian cancer biology, the genetic basis for hereditary ovarian cancer, staging and the role of cytoreductive surgery, and more effective chemotherapy, resulting in ...
openaire +2 more sources
Cancer Treatment Reviews, 2001
The treatment of ovarian cancer has evolved over the past two decades from one of palliation to one where patients can achieve prolonged remission and cure. Although prognosis remains poor, it has improved with the intervention of a multidisciplinary team and greater site specialization in the organization of cancer services.
J, Christian, H, Thomas
openaire +2 more sources
The treatment of ovarian cancer has evolved over the past two decades from one of palliation to one where patients can achieve prolonged remission and cure. Although prognosis remains poor, it has improved with the intervention of a multidisciplinary team and greater site specialization in the organization of cancer services.
J, Christian, H, Thomas
openaire +2 more sources
Current Opinion in Obstetrics and Gynecology, 1994
To reduce the mortality from ovarian cancer various studies by transvaginal color Doppler (TVCD) sonography and serum CA-125 tumor marker, alone or in combination, have been performed. Relatively poor specificities of CA-125 and transvaginal conventional sonography can be improved with the use of TVCD.
A, Kurjak, M, Predanic
openaire +2 more sources
To reduce the mortality from ovarian cancer various studies by transvaginal color Doppler (TVCD) sonography and serum CA-125 tumor marker, alone or in combination, have been performed. Relatively poor specificities of CA-125 and transvaginal conventional sonography can be improved with the use of TVCD.
A, Kurjak, M, Predanic
openaire +2 more sources
Current Treatment Options in Oncology, 2000
Epithelial ovarian cancer may appear to be confined to the ovaries or pelvis in approximately one-third of patients at exploration, but up to 30% of them will be upstaged following surgical staging. Substage and histotype are the most important prognostic factors that determine the need for adjuvant treatment.
G, Coukos, S C, Rubin
openaire +2 more sources
Epithelial ovarian cancer may appear to be confined to the ovaries or pelvis in approximately one-third of patients at exploration, but up to 30% of them will be upstaged following surgical staging. Substage and histotype are the most important prognostic factors that determine the need for adjuvant treatment.
G, Coukos, S C, Rubin
openaire +2 more sources
Clinical Obstetrics & Gynecology, 2012
Annual screening of asymptomatic postmenopausal women using a combination of transvaginal sonography and serum Ca-125 has been evaluated in 4 major clinical trials as a means to facilitate earlier detection of ovarian cancer. In several trials, screening has caused a decrease in stage at detection.
John R, van Nagell, Edward John, Pavlik
openaire +2 more sources
Annual screening of asymptomatic postmenopausal women using a combination of transvaginal sonography and serum Ca-125 has been evaluated in 4 major clinical trials as a means to facilitate earlier detection of ovarian cancer. In several trials, screening has caused a decrease in stage at detection.
John R, van Nagell, Edward John, Pavlik
openaire +2 more sources
Current Treatment Options in Oncology, 2000
State-of-the-art treatment for advanced ovarian cancer requires a multimodality approach. Aggressive surgical debulking with the goal of optimal cytoreduction is the initial step. After primary cytoreductive surgery, standard treatment for patients with stage III and IV disease is systemic combination chemotherapy consisting of six cycles of paclitaxel
D S, Chi, P, Sabbatini
openaire +2 more sources
State-of-the-art treatment for advanced ovarian cancer requires a multimodality approach. Aggressive surgical debulking with the goal of optimal cytoreduction is the initial step. After primary cytoreductive surgery, standard treatment for patients with stage III and IV disease is systemic combination chemotherapy consisting of six cycles of paclitaxel
D S, Chi, P, Sabbatini
openaire +2 more sources
Critical Reviews in Oncology/Hematology, 2009
At least 10% of ovarian tumors are hereditary and associated with highly penetrant, autosomal, dominant genetic predisposition. Three clinical manifestations of hereditary ovarian cancer have been identified: site-specific ovarian cancer, hereditary breast and/or ovarian cancer (HBOC) and hereditary non-polyposis colorectal cancer (HNPCC) syndromes ...
RUSSO, Antonio +5 more
openaire +2 more sources
At least 10% of ovarian tumors are hereditary and associated with highly penetrant, autosomal, dominant genetic predisposition. Three clinical manifestations of hereditary ovarian cancer have been identified: site-specific ovarian cancer, hereditary breast and/or ovarian cancer (HBOC) and hereditary non-polyposis colorectal cancer (HNPCC) syndromes ...
RUSSO, Antonio +5 more
openaire +2 more sources
The Lancet, 1969
Abstract A family is described in which 5 sisters and their mother had ovarian cancer. Prophylactic oophorectomy was done in five females in the next generation. None of the ovaries showed histological evidence of ovarian carcinoma.
A C, Lewis, B C, Davison
openaire +2 more sources
Abstract A family is described in which 5 sisters and their mother had ovarian cancer. Prophylactic oophorectomy was done in five females in the next generation. None of the ovaries showed histological evidence of ovarian carcinoma.
A C, Lewis, B C, Davison
openaire +2 more sources